Pharmacological Characterization of Human ml Muscarinic Acetylcholine Receptors with Double Mutations at the Junction of TM VI and the Third Extracellular Domain1

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 3, 1998, Pages 1129-1139

  Huang, X P ^a   Williams, F E ^a   Peseckis, S M ^a   Messer Jr , W S ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR; PHOSPHATIDYLINOSITOL; QUINUCLIDINYL BENZILATE; ACETYLCHOLINE; ARECOLINE; CARBACHOL; CHOLINE; HYOSCYAMINE; METHYLCARBACHOL; METHYLSCOPOLAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; MUTANT PROTEIN; NICOTINIC AGENT; OXOTREMORINE; OXOTREMORINE M; PILOCARPINE; PIRENZEPINE; TRIHEXYPHENIDYL;

AMINO ACID SEQUENCE; ARTICLE; CELL LINE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; BINDING AFFINITY; BINDING SITE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY;

AMINO ACID SEQUENCE; CELL LINE; HUMANS; MOLECULAR SEQUENCE DATA; MUSCARINIC AGONISTS; MUTATION; PHOSPHATIDYLINOSITOLS; PROTEIN CONFORMATION; QUINUCLIDINYL BENZILATE; RECEPTOR, MUSCARINIC M1; RECEPTORS, MUSCARINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032160565     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Allman K, Page KM and Hulme EC (1997) Cysteine scanning mutagenesis of transmembrane domain V of the ml muscarinic receptor. Life Sei 60:1177.
2. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC and Cesarman E (1997) Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385:347-350.
3. Bais C, Santomaso B, Coso 0, Arvanitakis L, Geras-Raakar E, Gutkind JS, Asch AS, Cesarman E, Gerhengorn MC and Mesri EA ( 1998) G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391:86-89.
4. Blüml K, Mutschier E and Wess J (1994) Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J Biol Chem 269:18870-18876.
5. Bonner TI, Young AC, Brann MR and Buckley NJ ( 1988) Cloning and expression of the human and rat m5 muscarinic acetylcholine genes. Neuron 1:450-455.
6. Brann MR, Buckley NJ, Jones SV and Bonner TI (1987) Expression of a cloned muscarinic receptor in A9 L cells. Mol Pharmacol 32:450-455.
7. Bulseco DA and Schimerlik MI (1996) Single amino acid substitutions in the pm2 muscarinic receptor/G protein coupling without changing physiological responses. Mol Pharmacol 49:132-141.
8. Burstein ES, Spalding TA, Braüner-Osborne H and Brann MR (1995) Constitutive activation of muscarinic receptors by the G-protein Gq. FEES Lett 363:261-263.
9. Chen C and Okayaraa H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7:2745-2752.
10. Cheng Y-C and Prusoff WH (1973) Relationship between the inhibition constant (K;) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
11. Dörje F, Wess J, Lambrecht G, Tacke R, Mutschier E and Brann MR (1991) Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther 256:727-733.
12. Dunbar PG, Durant GJ, Fang Z, Rho T, Abuh YF, El-Assadi AA, Ngur D, Periyasamy S, Hoss W and Messer WS Jr (1993) Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-l,2,4-oxadiazol-5-yl)-l,4,5,6-tetrahydropyrimidines as ml receptor agonists. J Med Chem 36:842-847.
13. Dunbar PG, Durant GJ, Rho T, Ojo B, Huzl JJ III, Smith DA, El-Assadi AA, Sbeih S, Ngur DO, Periyasamy S, Hoss W and Messer Jr WS (1994) Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbony)-l,4,5,6-tetrahydro-pyrimidines, as ml muscarinic receptor agonists. J Med Chem 37:2774-2782.
14. Fraser CM, Wang C-D, Robinson DA, Gocayne JD and Venter JC ( 1989) Site-directed mutagenesis of ml muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol Pharmacol 36:840-847.
15. Fromm C, Coso OA, Montaner S, Xu N and Gutkind JS (1997) The small GTPbinding protein Rho links G protein-coupled receptors and Gerl2 to the serum response element and to cellular transformation. Proc Natl Acad Sei USA 94: 10098-10103.
16. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H and Kobilka BK ( 1997) Structural instability of a constitutively active G protein-coupled receptor. J Biol Chem 272:2587-2590.
17. Högger P, Shockley MS, Lameh J and Sadée W (1995) Activating and inactivating mutations in N- and C-terminal 13 loop junctions of muscarinic acetylcholine Hml receptors. J Biol Chem 270:7405-7410.
18. Hoss W, Woodruff JM, Ellerbrock BR, Periyasamy S, Ghodsi-Hovsepian S, Stibbe J, Bohnett M and Messer Jr WS (1990) Biochemical and behavioral responses of pilocarpine at muscarinic receptor subtypes in the CNS. Comparison with receptor binding and low-energy conformations. Brain Res 533:232-238.
19. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG and Lefkowitz RJ (1992) Constitutive activation of the a1B-adrenergic receptor by all amino acid substitutions at a single site. J EM Chem 267:1430-1433.
20. Lowry O, Roserbough NJ, Farr AL and Ranall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
21. Markwell MA, Haas SM, Tolbert NE and Bieber LL (1981) Protein determination in membrane and lipoprotein samples: manual and automated procedures. Methods Enzymol 72:296-303.
22. Messer WS Jr and Dunbar PG (1996) Rationale for the design and development of amidine derivatives as selective muscarinic agonists, in Muscarinic Agonists and the Treatment of Alzheimer's Disease (Fisher A ed) pp 131-153, R. G. Landes Company, New York.
23. Messer WS Jr, Abuh YF, Liu Y, Periyasamy S, Ngur DO, Edgar MAN, El-Assadi AA, Sbeih S, Dunbar PG, Roknich S, Rho T, Fang Z, Ojo B, Zhang H, Huzl JJ III and Nagy PI (1997) Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydro-pyridine derivatives as selective ml agonists. J Med Chem 40:1230-1246.
24. Nordvall G and Hackseil U (1993) Binding-site modeling of the muscarinic ml receptor: A combination of homology-based and indirect approaches. J Med Chem 36:967-976.
25. Nordvall G and Hackseil U (1995) Binding-site modeling of the muscarinic ml receptor-molecular interactions with agonists and antagonists, in Molecular Mechanisms of Muscarinic Acetylcholine Receptor Function (Wess J ed) pp 19-32, R. G. Landes Company, Austin, TX.
26. Ferez DM, Hwa J, Gaivin R, Mathur M, Brown F and Graham RM (1996) Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol 49:112-122.
27. Samama P, Cotecchai S, Costa T and Lefkowitz RJ (1993) A mutation-induced activated state of the (32-adrenergic receptor. J Biol Chem 268:4625-4636.
28. Schwarz RD, Spencer CJ, Jaen JC, Mirzadegan T, Morland D, Tecle H and Thomas AJ (1995) Mutations of aspartate 103 in the Hm2 receptor and alternations in receptor binding properties of muscarinic agonists. Life Sei 56:923-929.
29. Shockley MS, Burford NT, Sadée W and Lameh J (1997) Residues specifically involved in down-regulation but not internalization of the ml muscarinic acetylcholine receptor. J Neurochem 68:601-609.
30. Spalding TA, Burstein ES, Brauner-Osborne H, Hill-Eubanks D and Brann MA (1995) Pharmacology of a constitutively activated muscarinic receptor generated by random mutagenesis. J Pharmacol Exp Ther 275:1274-1279.
31. Vogel WK, Sheehan DM and Schimerlik MI (1997) Site-directed mutagenesis of the m2 muscarinic acetylcholine receptor: The significance of Tyr403 in the binding of agonists and functional coupling. Mol Pharmacol 52:1087-1094.
32. Wang DX, Lerner-Marmarosh N, Sheu S-S, Sharma V, Jou M-J and Abood LG 119941 Differences in ligand binding and phosphoinositide turnover between ml muscarinic receptor gene transfected cells and mouse and rat brain membrane. Pharmacol Biochem Behav 49:405-411.
33. Ward JS, Merritt L, Klimkowski VJ, Lamb ML, Mitch CH, Bymaster FP, Sawyer B, Shannon HE, Olesen PH, Honore T, Sheardown MJ and Sauerbert P (1992) Novel functional Ml selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-l,2,5,6-tetrahydro-l-methylpyridines. Construction of a molecular model for the Ml pharamcophore. J Med Chem 35:4011-4019.
34. Ward SDC and Hulme EC (1997a) Alanine scanning mutagenesis in transmembrane domain six of the rat ml-muscarinic acetylcholine receptor (Rat mi-Receptor). Br J Pharmacol 120:284P.
35. Ward SDC and Hulme EC (1997b) Try381 in transmembrane domain six plays a key part in activation of the rat ml-muscarinic acetylcholine receptor, in Society For Neuroscience (s), pp 1750, Society For Neuroscience, Washington, D.C.
36. Wess J (1996) Molecular biology of muscarinic acetylcholine receptors. Critical Reviews in Neurobiology 10:69-99.
37. Wess J (1997) G-Protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 11:346-354.
38. Wess J, Gdula D and Brann MR (1991) Site-directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. EMBO J 10:3729-3737.
39. Wess J, Maggio R, Palmer JR and Vogel Z (1992) Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. J Biol Chem 267:19313-19319.
40. Wreggett KA and Irvine RFA (1987) Rapid separation method for inositol phosphates and their isomers. Biochem J 245:655-660.